Shares of Alphatec Holdings Inc (NASDAQ: ATEC) are soaring 5.02% in pre-market trading on Friday, following the company's impressive first-quarter 2025 results and an upward revision of its annual revenue forecast. The medical equipment manufacturer has demonstrated robust growth, outperforming market expectations and reinforcing investor confidence in its business trajectory.

Alphatec reported a 22.2% year-over-year increase in revenue, reaching $169.18 million for the quarter ended March 31, slightly surpassing analysts' expectations of $168.18 million. The company's surgical revenue grew by an impressive 24%, driven by a 17% increase in procedural volume and an 18% rise in surgeon adoption. Despite reporting a quarterly adjusted loss of 35 cents per share, which was wider than anticipated, the market appears to be focusing on the company's strong top-line growth and improved operational metrics.

The positive momentum is further supported by Alphatec's decision to raise its annual revenue forecast, signaling management's confidence in sustained growth. Additionally, Needham maintained its price target for Alphatec at $16.00 per share, while the Wall Street consensus price target stands at $19.00. With 11 out of 12 analysts rating the stock as "buy" or "strong buy," the market sentiment remains overwhelmingly positive for Alphatec as it continues to expand its market presence in the spine surgery sector.